Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;12(2):138-146.
doi: 10.1007/s13669-023-00350-1. Epub 2023 Feb 27.

Pharmacologic Treatment of Obesity in Reproductive Aged Women

Akua Nuako  1 , Lucy Tu  2   3 , Karen J Campoverde Reyes  4   5 , Shradha M Chhabria  6   7 , Fatima Cody Stanford  8   9   10
Affiliations

Pharmacologic Treatment of Obesity in Reproductive Aged Women

Akua Nuako et al. Curr Obstet Gynecol Rep. 2023 Jun.

Abstract

Purpose of review: This report will review existing literature on weight loss outcomes for various anti-obesity medications (AOMs) as well as their effects on human fertility, pregnancy, or breastfeeding.

Recent findings: There is a paucity of research on the effects of AOMs on human pregnancy and fertility. The majority of AOMs are not recommended during pregnancy and breastfeeding due to known or unclear risks of harm to offspring.

Summary: As the prevalence of obesity rises, AOMs have proven to be effective tools for weight loss in the general adult population. When prescribing AOMs to reproductive-aged women, providers should consider both the cardiometabolic benefits of these medications and potential effects that AOMs might have on hormonal contraception, pregnancy, or breastfeeding. Animal studies in rats, rabbits, and monkeys have suggested teratogenic effects of several medications discussed in this report. However, a lack of data on the use of many AOMs during human pregnancy or lactation makes it difficult to comment on the safety of their use in these time periods. Some AOMs show promise in promoting fertility while others might decrease the efficacy of oral contraceptives, highlighting some of the special considerations that must be taken when prescribing AOMs to reproductive-aged women. More research into the risks and benefits of AOMs in the context of reproductive-aged women's unique healthcare needs is an important step in improving this population's access to effective treatments for obesity.

Keywords: Anti-obesity agents; Bupropion; Liraglutide; Metformin; Naltrexone; Obesity; Orlistat; Pharmacotherapy; Phentermine; Plenity; Semaglutide; Tirzepatide; Topiramate; Women’s health; Zonisamide.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest The authors don’t have any conflict of interest.

References

    1. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. Centers for Disease Control and Prevention; 2020. p. 8. - PubMed
    1. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985–3023. 10.1016/j.jacc.2013.11.004. - DOI - PubMed
    1. Curioni CC, Lourenço PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond). 2005;29(10):1168–74. 10.1038/sj.ijo.0803015. - DOI - PubMed
    1. Prescription medications to treat overweight & obesity. https://www.niddk.nih.gov/health-information/weight-management/prescript.... Revised June 2021. Accessed 7 Aug 2022.
    1. Webb PM. Obesity and gynecologic cancer etiology and survival. Am Soc Clin Oncol Educ Book. 2013. 10.1200/EdBook_AM.2013.33.e222. - DOI - PubMed